Farmas USA

KERX

Cambio de CEO y previsión datos ventas Q1 2018 

Keryx Biopharmaceuticals Announces Changes to Management and Preliminary First Quarter 2018 Revenue

• Gregory Madison resigned as president and chief executive officer of the company and from its board of directors
• Jodie Morrison, current Keryx board member, named interim chief executive officer
• Company expects to report first quarter 2018 total revenue of $21.0 million - $22.5 million, including Auryxia®net U.S. product sales of $20.0 million - $21.0 million

https://keryx.gcs-web.com/news-releases/news-release-details/keryx-biopharmaceuticals-announces-changes-management-and

REGN

has accepted for priority review BLA for cemiplimab for the treatment of patients with metastatic cutaneous squamous cell carcinoma. Pdufa date: October 28, 2018

https://finance.yahoo.com/news/fda-conduct-priority-review-cemiplimab-050000137.html

TEVA

Leo en un Twitter de Zacks:

*ALLERGAN PLANS ORDERLY SALE OF REMAINING 34 MILLION TEVA SHARES

a ver si ayuda a reanimar al zombie .... REGN

KERX ...  al final el HCH que estaba formando salto por los aires. A ver como desarrolla sesion pero no pago mas de 4,00 y no creo que la compre hoy.

Keryx sees up to $21M in Q1 Auryxia sales; shares down 12% on CEO departure

Keryx Biopharmaceuticals (NASDAQ: KERX) is down 12% premarket on light volume on the heels of its  announcement of preliminary Q1 results and the resignation of President & CEO Greg Madison.

Revenues should be $21.0M - 22.5M compared to consensus of ~$22M. Auryxia sales are expected to be $20.0 - 21.0M. Complete results will be released in the coming weeks.

Board member Jodie Morrison will take the helm on an interim basis until a permanent successor to Mr. Madison is appointed.

Previously:  FDA OK of expanded use of Auryxia can't overcome Q3 miss and withdrawal of guidance; shares down 12% premarket (Nov. 7, 2017)

SGYP

Creo que no se había comentado por aquí que cambió las condiciones del préstamo y ya no necesita presentar los 100 millones cada X.

Synergy reports earnings May 10. With shares trading at historic lows, expectations are not high and trust in management is nonexistent.

The company has promised material improvements in prescription growth of constipation drug Trulance, but a Bloomberg tracker shows slow progress.

Investors should pay close attention to revenue and prescription growth numbers, cash burn, and partnership and licensing progress.

Synergy's market cap is now well below the value of Trulance’s projected peak sales. This creates significant opportunity for activism, takeover, or licensing partnership.

Synergy owns a very valuable asset, which is mispriced by the market even after accounting for management’s poor commercial execution.

https://seekingalpha.com/article/4167373-synergy-pharmaceuticals-q1-earnings-preview

KERX velas 2h

Asunto HCH

AKAO

Para los de MLNT o si alguien la sigue. Acaban de salir el briefing para la PFUFA: 2 de mayo

https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Anti-InfectiveDrugsAdvisoryCommittee/UCM606039.pdf

La veo en +10% en pre. Por ahí se lee en positivo, pero, sin seguirla, añado que veo una labeling especial marcado en fosforito tal y como está redactado.

ACAD

canal ascendente en 30/60 min que empieza a tomar forma para una Bear Flag.

Necesitamos el MACD de 2h tirando a bullish ( a este ritmo , si se mantuviera, podria ser hoy ) ... para que el precio rompa el canal por arriba y no para el otro lado ...

A ver que pasa ...  como saquen otra pieza los de la CNN nos terminan de rematar.